Effect of creatine monohydrate on clinical progression in patients with parkinson disease: A randomized clinical trial

JAMA - Journal of the American Medical Association

Volumn 313, Issue 6, 2015, Pages 584-593

  Kieburtz, Karl ^a   Tilley, Barbara C ^b   Elm, Jordan J ^c   Babcock, Debra ^d   Hauser, Robert ^e   Ross, G Webster ^f   Augustine, Alicia H ^a   Augustine, Erika U ^a   Aminoff, Michael J ^g   Bodis Wollner, Ivan G ^h   Boyd, James ⁱ   Cambi, Franca ^j   Chou, Kelvin ^k   Christine, Chadwick W ^g   Cines, Michelle ^l   Dahodwala, Nabila ^m   Derwent, Lorelei ⁿ   Dewey, Richard B ^o   Hawthorne, Katherine ^p   Houghton, David J ^q   Kamp, Cornelia ^a   Leehey, Maureen ^r   Lew, Mark F ^p   Lin Liang, Grace S ^s   Luo, Sheng T ^b   Mari, Zoltan ^t   Morgan, John C ^u   Parashos, Sotirios ^v   Pérez, Adriana ^b   Petrovitch, Helen ^f   Rajan, Suja ^b   Reichwein, Sue ^m   Roth, Jessie Tatsuno ^g   Schneider, Jay S ^w   Shannon, Kathleen M ^x   Simon, David K ^y   Simuni, Tanya ^z   Singer, Carlos ^aa   Sudarsky, Lewis ^ab   Tanner, Caroline M ^s   Umeh, Chizoba C ^ab   Williams, Karen ^z   Wills, Anne Marie ^ab   more..

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e UNIVERSITY OF SOUTH FLORIDA   (United States)

^f Pacific Health Research and Education Institute   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h SUNY DOWNSTATE MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF VERMONT   (United States)

^j UNIVERSITY OF KENTUCKY   (United States)

^k UNIVERSITY OF MICHIGAN   (United States)

^l UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^m UNIVERSITY OF PENNSYLVANIA   (United States)

ⁿ UNIVERSITY OF CALGARY   (Canada)

^o UNIVERSITY OF TEXAS AT DALLAS   (United States)

^p UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^q OCHSNER MEDICAL CENTER   (United States)

^r UNIVERSITY OF COLORADO   (United States)

^s PARKINSON S INSTITUTE   (United States)

^t JOHNS HOPKINS UNIVERSITY   (United States)

^u AUGUSTA UNIVERSITY   (United States)

^v Struthers Parkinson's Centre   (United States)

^w THOMAS JEFFERSON UNIVERSITY   (United States)

^x RUSH UNIVERSITY MEDICAL CENTER   (United States)

^y BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^z NORTHWESTERN UNIVERSITY   (United States)

^aa UNIVERSITY OF MIAMI   (United States)

^ab BRIGHAM AND WOMEN S HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE; PLACEBO; ANTIPARKINSON AGENT;

ADULT; ARTHROPATHY; ARTICLE; BLOOD CLOTTING FACTOR 5 DEFICIENCY; BONE DISEASE; CONGENITAL DISORDER; CONTROLLED STUDY; CORONARY ARTERY ANOMALY; DIASTEMATOMYELIA; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EAR DISEASE; ENDOCRINE DISEASE; EYE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; GENITAL SYSTEM DISEASE; GILBERT DISEASE; HEART DISEASE; HEMATOLOGIC DISEASE; HEPATOBILIARY DISEASE; HUMAN; IMMUNOPATHOLOGY; INFECTION; INFESTATION; INJURY; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC DISORDER; MULTICENTER STUDY; MUSCLE DISEASE; NEOPLASM; NEUROLOGIC DISEASE; NEUROPATHY; NUTRITIONAL DISORDER; PARKINSON DISEASE; PATIENT COMPLIANCE; PREGNANCY DISORDER; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SKIN DISEASE; TREATMENT OUTCOME; URINARY TRACT DISEASE; VASCULAR DISEASE; AGED; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG COMBINATION; FOLLOW UP; MEDICATION COMPLIANCE; MIDDLE AGED;

AGED; ANTIPARKINSON AGENTS; CREATINE; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 84922485882     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.120     Document Type: Article

References (31)

1. Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68(5):384-386.
2. Kowal SL, Dall TM, Chakrabarti R, StormMV, Jain A. The current and projected economic burden of Parkinson's disease in the United States. Mov Disord. 2013;28(3):311-318.
3. Ravina BM, Fagan SC, Hart RG, et al. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology. 2003;60(8):1234-1240.
4. NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology. 2006;66(5):664-671.
5. NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology. 2007;68(1):20-28.
6. NINDS NET-PD Investigators. A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. Clin Neuropharmacol. 2008;31(3):141-150.
7. Tilley BC, Palesch YY, Kieburtz K, et al; NET-PD Investigators. Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs. Neurology. 2006;66(5):628-633.
8. Elm JJ; NINDS NET-PD Investigators. Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1. Mov Disord. 2012;27(12):1513-1521.
9. Huang P, Goetz CG, Woolson RF, et al; Parkinson Study Group. Using global statistical tests in long-term Parkinson's disease clinical trials. Mov Disord. 2009;24(12):1732-1739.
10. Schwab R, England A. Projection technique for evaluating surgery in Parkinson's disease. In: Gillingham F, Donaldson I, eds. Third Symposium on Parkinson's Disease. Edinburgh, Scotland: E & S Livingstone; 1969:152-157.
11. Bushnell DM, Martin ML. Quality of life and Parkinson's disease: translation and validation of the US Parkinson's Disease Questionnaire (PDQ-39). Qual Life Res. 1999;8(4):345-350.
12. Jenkinson C, Fitzpatrick R, Norquist J, Findley L, Hughes K. Cross-cultural evaluation of the Parkinson's Disease Questionnaire: tests of data quality, score reliability, response rate, and scaling assumptions in the United States, Canada, Japan, Italy, and Spain. J Clin Epidemiol. 2003;56(9):843-847.
13. Fahn S, Elton R; UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Marsden S, Calne D, Goldstein M, eds. Recent Developments in Parkinson's Disease. Florham Park, NJ: Macmillan Healthcare Information; 1987: 153-163.
14. Smith A. Symbol Digit Modalities Test Manual. Los Angeles, CA:Western Psychological Services; 2002.
15. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19(5):604-607.
16. Marinus J, Visser M, Verwey NA, et al. Assessment of cognition in Parkinson's disease. Neurology. 2003;61(9):1222-1228.
17. EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199-208.
18. Shoulson I, Kurlan R, Rubin A, et al. Assessment of functional capacity in neurodegenerative movement disorders: Huntington's disease as a prototype. In: Munsat T, ed. Quantification of Neurologic Deficit. Boston, MA: Butterworths; 1989:271-283.
19. Beck AT, Steer RA, Ball R, RanieriW. Comparison of Beck Depression Inventories-IA and-II in psychiatric outpatients. J Pers Assess. 1996; 67(3):588-597.
20. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord. 2010;25(15):2649-2653.
21. Huang P, Tilley BC, Woolson RF, Lipsitz S. Adjusting O'Brien's test to control type I error for the generalized nonparametric Behrens-Fisher problem. Biometrics. 2005;61(2):532-539.
22. Lan KK, Wittes J. The B-value: a tool for monitoring data. Biometrics. 1988;44(2):579-585.
23. Ellenberg SS, Fleming TR, DeMets DL. Data Monitoring Committees in Clinical Trials: A Practical Perspective. London, United Kingdom: John Wiley & Sons; 2002.
24. Luo S, Lawson AB, He B, Elm JJ, Tilley BC. Bayesian multiple imputation for missing multivariate longitudinal data from a Parkinson's disease clinical trial [published online December 18, 2012]. Stat Methods Med Res. doi:10.1177/0962280212469358.
25. Whitehead J. The Design and Analysis of Sequential Clinical Trials. Rev 2nd ed. Chichester, United Kingdom: John Wiley & Sons; 1997.
26. Krige D, Carroll MT, Cooper JM, Marsden CD, Schapira AH; Royal Kings and Queens Parkinson Disease Research Group. Plateletmitochondrial function in Parkinson's disease. Ann Neurol. 1992;32 (6):782-788.
27. ParkerWD Jr, Boyson SJ, Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol. 1989;26 (6):719-723.
28. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD.Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem. 1990;54(3):823-827.
29. Klivenyi P, Gardian G, Calingasan NY, Yang L, Beal MF. Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl- 1, 2, 3, 6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. J Mol Neurosci. 2003;21(3):191-198.
30. Matthews RT, Ferrante RJ, Klivenyi P, et al. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol. 1999;157(1):142-149.
31. Gray R, Ives N, Rick C, et al; PDMed Collaborative Group. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet. 2014;384(9949):1196-1205.